DDInter413 DDInter899
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Clopidogrel {u} may lead to a major life threatening interaction when taken with {v} Ticlopidine
Clopidogrel {u} (Compound) treats {v} (Disease) coronary artery disease
Clopidogrel {u} (Compound) binds {v} (Gene) P2RY12
Clopidogrel {u} (Compound) upregulates {v} (Gene) TBXA2R
Clopidogrel {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Clopidogrel {u} (Compound) downregulates {v} (Gene) DECR1
Clopidogrel {u} (Compound) causes {v} (Side Effect) Deafness
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluvastatin
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Modafinil
Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Clopidogrel (Compound) treats coronary artery disease (Disease)
Clopidogrel (Compound) binds P2RY12 (Gene)
Clopidogrel (Compound) upregulates TBXA2R (Gene)
Clopidogrel (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Clopidogrel (Compound) downregulates DECR1 (Gene)
Clopidogrel (Compound) causes Deafness (Side Effect)
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fluvastatin
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Torasemide
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Modafinil